Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05843643 · ClinicalTrials.gov registry record · Phase 3
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
A Phase 3 study of Systemic Lupus Erythematosus, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT05843643 is a Phase 3 study of Systemic Lupus Erythematosus that is actively recruiting participants, run by AbbVie. The registered enrollment target is 1,000 participants, above the 370-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (170% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT05843643, a Phase 3 study of Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo (does not contain treatment drug) . This study comprised of 4 sub studies. In Study 1 and Study 2, study doctors put the participants in 1 of the 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. Eligible participants from Study 1 and Study 2 will enter Study 3 at week 52 to receive specific doses of upadacitinib. Study 4 is a 104-week continued extension if participation is likely to provide a benefit to their SLE. Approximately 500 participants diagnosed with SLE will be enrolled in each of the Study 1 and Study 2 in approximately 320 sites across the world. Participants will receive oral tablets of upadacitinib or matching placebo once daily for 52 weeks in Study 1 and Study 2. Eligible participants from Study 1 and Study 2 will receive oral tablets of upadacitinib once daily for 52 weeks in Study 3. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Upadacitinib
Study Locations (20)
Arizona
- AZ Arthritis and Rheumatology /ID# 261848 - Chandler
- AZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 254767 - Flagstaff
- Arizona Arthritis & Rheumatology Research, PLLC /ID# 252820 - Gilbert
- Arizona Arthritis and Rheumatology Research - Glendale Office /ID# 252824 - Glendale
- Arizona Arthritis & Rheumatology Research, PLLC /ID# 261845 - Mesa
- Arizona Arthritis & Rheumatology Research /ID# 273555 - Peoria
- Arizona Arthritis & Rheumatology Associates - East Bell Road /ID# 252831 - Phoenix
- Arizona Arthritis & Rheumatology Research, PLLC /ID# 252825 - Phoenix
- HonorHealth Rheumatology /ID# 261953 - Scottsdale
- Arizona Arthritis & Rheumatology Associates - Tucson /ID# 252828 - Tucson
California
- Kaiser Permanente Lakeview Medical Offices /ID# 253906 - Anaheim
- David S. Hallegua MD, A Professional Corporation /ID# 253902 - Beverly Hills
- Wallace and Lee Center /ID# 275129 - Beverly Hills
- Wallace Rheumatic Studies Center, LLC /ID# 252806 - Beverly Hills
- Advanced Clinical Research Center, LLC dba TriWest Research Associates /ID# 272870 - Chula Vista
- Providence - St. Jude Medical Center /ID# 252822 - Fullerton
- Private Practice - Dr. Chandrakant V. Mehta /ID# 275100 - Hemet
- Newport Huntington Medical Group /ID# 252827 - Huntington Beach
- Moores Cancer Center at UC San Diego /ID# 253903 - La Jolla
Arkansas
- Arthritis and Rheumatism Associates /ID# 253033 - Jonesboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2023-07-19 |
| Est. Completion | 2027-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05843643
The ClinicalTrials.gov registry entry for NCT05843643 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 370-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (170% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05843643 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Arizona, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05843643 about?
NCT05843643 is a clinical study titled "Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus". Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activ...
What is the current status of trial NCT05843643?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2023-07-19. Estimated completion is 2027-10.
What conditions does trial NCT05843643 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT05843643?
The interventions under investigation include: Placebo (DRUG), Upadacitinib (DRUG).
Who is sponsoring clinical trial NCT05843643?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05843643 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
RECRUITING · Phase 3
-
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.